CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
Nintedanib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02496585
NCT02496585Phase 2Completed
CompareCT.gov

Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis

Memorial Sloan Kettering Cancer Center·interventional·Posted Jul 14, 2015·Updated Apr 16, 2025

In Brief

A Phase 2 clinical trial evaluating Nintedanib, Prednisone, and 1 other intervention for Lung Cancer and Lung Metastases. Completed, enrolled 34 participants across 12 sites.

Detailed Summary

The purpose of this study is to find out what effects, good and/or bad, the drug nintedanib in combination with steroids, has on the lungs. Furthermore, such treatments' side effects will be studied together with quality of life. In addition, the investigators would like to determine whether they can find markers in the blood which predict worsening lung injury.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Lung Metastases
CountriesUnited States
CollaboratorsBoehringer Ingelheim

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 14, 2015
Enrollment StartJul 8, 2015
Primary CompletionApr 12, 2024
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 11.0 years ago

Interventions

Nintedanibdrug

Prednisonedrug

Placeboother